Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.38 |
| ▸ | TLR3 | O15455 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22886426 | 0.92 | FTO (0.42) | ALDH1A1CAPN1 | |
| SCHEMBL20028068 | 0.91 | CAPN1 (0.48) | ALDH1A1CAPN1CA2SCN9A | |
| SCHEMBL22886096 | 0.88 | CAPN1 (0.51) | CAPN1 | |
| SCHEMBL22886730 | 0.86 | L3MBTL1 (0.41) | CAPN1 | |
| SCHEMBL22885869 | 0.83 | CAPN1 (0.40) | CAPN1PSMB5ITGB1ITGA4 | |
| SCHEMBL20028431 | 0.83 | CAPN1 (0.53) | CAPN1 | |
| SCHEMBL21854063 | 0.83 | CAPN1 (0.53) | CAPN1 | |
| SCHEMBL22945879 | 0.83 | SCN9A (0.38) | ALDH1A1CAPN1CA2PSMB5USP30 | |
| SCHEMBL20028398 | 0.82 | CAPN1 (0.45) | ALDH1A1CAPN1CA2 | |
| SCHEMBL21410716 | 0.81 | FTO (0.42) | ALDH1A1CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | ALDH1A1 4344/4885CAPN1 3/4885CA2 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.